Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance Marks a key step forward for the world's first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with...

menu
menu